These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 21118870)

  • 1. Setting the research agenda for future clinical trials on the use of biologics in rheumatology.
    Silman A; Rudkin S; Walley T
    Rheumatology (Oxford); 2011 Aug; 50(8):1356-7. PubMed ID: 21118870
    [No Abstract]   [Full Text] [Related]  

  • 2. [Tolerance of anti-TNF alpha: the experience acquired in inflammatory rheumatic disease].
    Mariette X
    Ann Dermatol Venereol; 2006 May; 133(5 Pt 2):1S8-12. PubMed ID: 16967603
    [No Abstract]   [Full Text] [Related]  

  • 3. [TNF-alpha antagonists in therapy of rheumatoid arthritis].
    Gross WL; Gause A
    Z Rheumatol; 2003 Jun; 62(3):217. PubMed ID: 12931691
    [No Abstract]   [Full Text] [Related]  

  • 4. MonitorNet: the Italian multi-centre observational study aimed at estimating the risk/benefit profile of biologic agents in real-world rheumatology practice.
    Sfriso P; Salaffi F; Montecucco CM; Bombardieri S; Todesco S
    Reumatismo; 2009; 61(2):132-9. PubMed ID: 19633800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical trials in rheumatology. Does one size fit all?
    Tombetti E; Rovere-Querini P; Manfredi AA
    Rheumatology (Oxford); 2017 May; 56(5):675-676. PubMed ID: 27313279
    [No Abstract]   [Full Text] [Related]  

  • 6. Developing anti-TNF and biologic agents.
    Taylor PC
    Rheumatology (Oxford); 2011 Aug; 50(8):1351-3. PubMed ID: 21746890
    [No Abstract]   [Full Text] [Related]  

  • 7. [Biological treatment of rhematoid diseases].
    Pavelka K
    Vnitr Lek; 2006 Jun; 52(6):561-2. PubMed ID: 16871758
    [No Abstract]   [Full Text] [Related]  

  • 8. [News in rheumatology. The Danish Society of Rheumatology].
    Østergaard M; Steengaard-Pedersen K; Herlin T; Kjaer M; Døhn UM; Nørregaard J; Madsen OR;
    Ugeskr Laeger; 2007 Mar; 169(12):1131. PubMed ID: 17394842
    [No Abstract]   [Full Text] [Related]  

  • 9. The 2005 International Symposium on Advances in Targeted Therapies: what have we learned in the 2000s and where are we going?
    Maini RN
    Ann Rheum Dis; 2005 Nov; 64 Suppl 4():iv106-8. PubMed ID: 16239377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Editorial: the vital role of randomized controlled trials in Arthritis & Rheumatology.
    Solomon DH; Weinblatt ME; Bucala RJ
    Arthritis Rheumatol; 2015 Oct; 67(10):2555-6. PubMed ID: 26139424
    [No Abstract]   [Full Text] [Related]  

  • 11. Are individual patient trials (n-of-1 trials) in rheumatology worth the extra effort?
    Peloso PM
    J Rheumatol; 2004 Jan; 31(1):8-11. PubMed ID: 14705210
    [No Abstract]   [Full Text] [Related]  

  • 12. Comment on prescribing tumor necrosis factor inhibitors.
    Hanauer LB
    Arthritis Rheum; 2002 Jun; 47(3):347-8. PubMed ID: 12115169
    [No Abstract]   [Full Text] [Related]  

  • 13. Is there a rationale for switching from one anti-tumor necrosis factor agent to another?
    Haraoui B
    J Rheumatol; 2004 Jun; 31(6):1021-2. PubMed ID: 15170907
    [No Abstract]   [Full Text] [Related]  

  • 14. Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005.
    Furst DE; Breedveld FC; Kalden JR; Smolen JS; Burmester GR; Bijlsma JW; Dougados M; Emery P; Keystone EC; Klareskog L; Mease PJ
    Ann Rheum Dis; 2005 Nov; 64 Suppl 4(Suppl 4):iv2-14. PubMed ID: 16239380
    [No Abstract]   [Full Text] [Related]  

  • 15. Introduction to special section: biologic agents in the treatment of rheumatic diseases-the first decade.
    Yelin E; Katz P
    Arthritis Rheum; 2009 May; 61(5):559. PubMed ID: 19405010
    [No Abstract]   [Full Text] [Related]  

  • 16. Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004.
    Furst DE; Breedveld FC; Kalden JR; Smolen JS; Burmester GR; Bijlsma JW; Dougados M; Emery P; Keystone EC; Klareskog L; Mease PJ
    Ann Rheum Dis; 2004 Nov; 63 Suppl 2(Suppl 2):ii2-ii12. PubMed ID: 15479866
    [No Abstract]   [Full Text] [Related]  

  • 17. [Biological treatment of rheumatic diseases].
    Procházková L; Böhmová J; Soucek M
    Vnitr Lek; 2006 Jun; 52(6):632-9. PubMed ID: 16871769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of biologics in rheumatology: improving the evidence base.
    Silman AJ; Ades AE
    Rheumatology (Oxford); 2011 Sep; 50 Suppl 4():iv1-2. PubMed ID: 21859699
    [No Abstract]   [Full Text] [Related]  

  • 19. The perioperative use of biologic agents in patients with rheumatoid arthritis.
    Polachek A; Caspi D; Elkayam O
    Autoimmun Rev; 2012 Dec; 12(2):164-8. PubMed ID: 22522087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Non-TNF biologicals in therapy].
    Wollenhaupt J; Burmester GR
    Z Rheumatol; 2010 Sep; 69(7):579-80. PubMed ID: 20703491
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.